Amgen Inc. $AMGN Shares Bought by King Luther Capital Management Corp

King Luther Capital Management Corp grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 509,158 shares of the medical research company’s stock after purchasing an additional 1,653 shares during the quarter. King Luther Capital Management Corp owned approximately 0.09% of Amgen worth $143,684,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Sequoia Financial Advisors LLC lifted its stake in shares of Amgen by 2.3% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after purchasing an additional 3,619 shares during the period. Atlantic Union Bankshares Corp lifted its position in Amgen by 165.0% during the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after buying an additional 6,627 shares during the period. Davis Capital Management acquired a new stake in Amgen in the 3rd quarter worth about $1,841,000. D.A. Davidson & CO. grew its holdings in Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after buying an additional 6,222 shares during the period. Finally, Global Wealth Management Investment Advisory Inc. increased its stake in shares of Amgen by 56.2% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock valued at $3,684,000 after acquiring an additional 4,699 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent analyst reports. BMO Capital Markets boosted their target price on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Mizuho lifted their target price on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. DZ Bank lifted their price objective on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Finally, Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $351.83.

Amgen Trading Up 1.7%

AMGN opened at $379.73 on Thursday. The firm has a market capitalization of $204.70 billion, a P/E ratio of 26.69, a P/E/G ratio of 3.82 and a beta of 0.46. The firm’s 50 day moving average is $340.91 and its 200-day moving average is $315.28. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.